AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22348845
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml 0.75% ropivacaine to the tonsil lodge
Trial: 22348845
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg i.v. tramadol
Trial: 21054850
Drug: Selective V(2)R-antagonist
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective V(2)R-antagonist (1 μg/kg per hour)
Trial: 21054850
Drug: AVP (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP (0.05 μg/kg per hour)
Trial: 10686834
Drug: Presurgical oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical oral health (OHSQ)
Trial: 8363468
Drug: Multivitamin/mineral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/mineral supplement
Trial: 31917319
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement
Trial: 10709535
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (injection given in a slow manner without the distraction technique)
Trial: 1683217
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day oral celiprolol
Trial: 1683217
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day oral nicardipine
Trial: 31198048
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity coaching program (18 months, monthly follow-up by physiotherapist)
Trial: 23720981
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate supplementation (50 mg per meal, three times a day)
Trial: 21083540
Drug: Ketorolac (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.5 mg/kg bolus, 83.3 microg/kg/h infusion for 48 h)
Trial: 21083540
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 microg/kg bolus, 0.17 microg/kg/h infusion for 48 h)
Trial: 15534261
Drug: Antioxidants (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg)
Trial: 15534261
Drug: Zinc and
RxNorm normalized name: Zinc and/or zinc compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc and copper (zinc, 80 mg; cupric oxide, 2 mg)
Trial: 31606455
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (OCA) 5 to 10 mg daily
Trial: 21735193
Drug: Acetic acid-moistened
RxNorm normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetic acid-moistened misoprostol tablets
Trial: 21735193
Drug: Dry misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry misoprostol tablets
Trial: 15136504
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment (MTP-493GG genotype)
Trial: 29570475
Drug: Control (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (high-dose corticosteroids)
Trial: 23299763
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid)
Trial: 23299763
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with high basal free radicals
Trial: 23299763
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with low basal free radicals
Trial: 12639160
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba 120 mg
Trial: 11043871
Drug: Additional-exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional-exercise treatment group (AT group)
Trial: 11043871
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment group (RT group)
Trial: 9124404
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor (IGF-I) 100 microg/kg subcutaneously every 12 h for 6 doses
Trial: 9702254
Drug: Antiviral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral and immunostimulative treatment with Romanian specific products
Trial: 27419471
Drug: fractional laser
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fractional laser plus topical lidocaine cream (Group LaserAnes)
Trial: 27419471
Drug: sham irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sham irradiation plus topical anesthesia (Group Anes)
Trial: 18006189
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg orally dissolving tablet)
Trial: 16356219
Drug: Post-operative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative goal-directed therapy (GDT)
Trial: 1675329
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy home service (6-week comprehensive programme)
Trial: 1675329
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for 6 weeks)
Trial: 29411520
Drug: 0.02% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% triamcinolone acetonide cream
Trial: 26932305
Drug: Vildagliptin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin FDC tablets (50/250 mg)
Trial: 26932305
Drug: Vildagliptin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin FDC tablets (50/500 mg)
Trial: 26932305
Drug: Vildagliptin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin FDC tablets (50/500 mg) after meals
Trial: 26932305
Drug: Metformin under
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin under fed condition
Trial: 17488783
Drug: Psychodynamic interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic interpersonal therapy
Trial: 19829284
Drug: 5-HT4 agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT4 agonists
Trial: 16084157
Drug: eptifibatide +
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eptifibatide + tenecteplase (0.25 mg/kg intravenous bolus)
Trial: 12373040
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) consisting of transdermal application of continuous 17beta‐estradiol with cyclic medroxyprogesterone acetate (MPA) tablets for 14 days every 3rd month
Trial: 10197835
Drug: Pindolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5 mg 3 times daily) for 10 days
Trial: 10197835
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily) for 10 days
Trial: 2179850
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin E (dl-alpha-tocopherol) on days 1, 2, 4, and 6 of life
Trial: 2179850
Drug: Intramuscular placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placebo injections on the same schedule
Trial: 2179850
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E treatment in survivors
Trial: 30281813
Drug: Tooth brushing
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth brushing once daily
Trial: 30281813
Drug: Tooth brushing
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth brushing twice daily
Trial: 30281813
Drug: Tooth brushing
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth brushing three times daily
Trial: 24219618
Drug: High-dose paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose paracetamol (40 mg/kg body weight, max 2000 mg)
Trial: 24219618
Drug: High-dose paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose paracetamol
Trial: 22948036
Drug: UDCA (13‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (13‐15 mg/kg/day for 4 weeks)
Trial: 20739431
Drug: Bortezomib after
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib after high-dose melphalan
Trial: 20739431
Drug: Bortezomib before
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib before high-dose melphalan
Trial: 18188757
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy overnight
Trial: 18188757
Drug: Treatments that
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments that improve sleep quality
Trial: 9196769
Drug: Mefloquine 250
RxNorm normalized name: mefloquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 250 mg weekly
Trial: 1330396
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (solution, fasted)
Trial: 1330396
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (capsule with food)
Trial: 1330396
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (capsule without food)
Trial: 1330396
Drug: Equiactive metabolite
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment A
Trial: 1330396
Drug: Equiactive metabolite
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment B
Trial: 1330396
Drug: Equiactive metabolite
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment C
Trial: 31342474
Drug: 19 G
RxNorm normalized name: Sharps Collector 19 Gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 G Franseen-tip core biopsy needle (FNB)
Trial: 31342474
Drug: 19 G
RxNorm normalized name: Sharps Collector 19 Gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 G aspiration needle (FNA)
Trial: 29852863
Drug: Omega-3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (300 mg daily)
Trial: 24898101
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral antibiotic switch (group A)
Trial: 24898101
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous antibiotics (group B)
Trial: 22940436
Drug: Electrically Heated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K6 cigarette (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Trial: 22940436
Drug: Electrically Heated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K3 cigarette (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Trial: 22940437
Drug: Marlboro cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Trial: 18294729
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (3 L/minute)
Trial: 11798671
Drug: Captopril (12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5mg three times daily)
Trial: 1746790
Drug: Ranitidine elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine elixir 3 mg/kg via nasogastric tube every 12 hours
Trial: 1746790
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ranitidine 1 mg/kg every 8 hours
Trial: 6700849
Drug: Single 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-g preoperative dose of cefoxitin
Trial: 6700849
Drug: Three 2-g
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three 2-g doses of cefoxitin over 12 hours
Trial: 29948596
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil treatment applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Trial: 30275687
Drug: 24-week multicomponent
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24-week multicomponent intervention (group exercise, nutritional supplementation, depression management, deprescribing medications, home hazard reduction)
Trial: 21343348
Drug: Etamicastat (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat (2, 10, 20, 50, 100, 200, 400, 600, 900, or 1200 mg)
Trial: 21343348
Drug: Etamicastat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat (100 mg and above)
Trial: 20339359
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction (BMI reduction by 1 SDS, n = 51; and 2 SDS, n = 21) under conservative treatment for 18 months.
Trial: 1744867
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg timolol orally
Trial: 30045259
Drug: Melatonin (ML)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (ML)
Trial: 26162825
Drug: EVICEL™ applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVICEL™ applied during surgery (5 ml)
Trial: 26162825
Drug: Electrocoagulation (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocoagulation (standard treatment)
Trial: 20673353
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (28 day cycles of cyclophosphamide, methotrexate and 5‐fluorouracil)
Trial: 20673353
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no specific treatment mentioned)
Trial: 18486740
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg every 8 weeks (for partial responders)
Trial: 18486740
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg every 12 weeks (for partial responders)
Trial: 18486740
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (for partial responders)
Trial: 12531444
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g IV at induction of anesthesia)
Trial: 12531444
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g IV at induction of anesthesia)
Trial: 11064186
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg sublingual buprenorphine + 0 mg naloxone
Trial: 11064186
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg sublingual buprenorphine + 4 mg naloxone
Trial: 11064186
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg sublingual buprenorphine + 8 mg naloxone
Trial: 11064186
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine + naloxone
Trial: 11064186
Drug: Buprenorphine bioavailability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine bioavailability
Trial: 11064186
Drug: Naloxone bioavailability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone bioavailability
Trial: 1788149
Drug: DDAVP (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Trial: 7101088
Drug: Cefonicid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1 g, intramuscularly)
Trial: 7101088
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin G (4.8 x 10^6 units) plus probenecid (1.0 g)
Trial: 30209152
Drug: Oral TN-TC11M
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral TN-TC11M (THC 2.5mg/CBD 2.5mg) capsules
Trial: 27871549
Drug: Epidural chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural chloroprocaine 1.2% mixed with 0.4μg/mL fentanyl
Trial: 18795916
Drug: V. filiformis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V. filiformis cream 5%
Trial: 16176175
Drug: zidovudine+lamivudine treatment
RxNorm normalized name: lamivudine / zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zidovudine+lamivudine treatment
Trial: 16176175
Drug: didanosine+stavudine treatment
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: didanosine+stavudine treatment
Trial: 15184979
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg once daily for 6 weeks)
Trial: 10447629
Drug: Classic nail
RxNorm normalized name: FUNGI NAIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic nail (intramedullary implant) for fixation of peritrochanteric fractures
Trial: 1693762
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg and 10 mg of heroin
Trial: 1693762
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg and 2 mg of hydromorphone
Trial: 1693762
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of the same drug
Trial: 1693762
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of the alternate drug
Trial: 1693762
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (heroin and hydromorphone)
Trial: 489201
Drug: Metoprolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 40 mg orally
Trial: 30359681
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneously every 4 weeks plus standard of care
Trial: 23498594
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCSs) treatment during acute LRTIs, n = 70
Trial: 23498594
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with OCSs during acute LRTIs, n = 42
Trial: 23498594
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCSs) treatment during severe LRTIs, n = 133 (from the second cohort)
Trial: 15293971
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg as a single dose)
Trial: 15293971
Drug: Mebendazole (Janssen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (Janssen, 100 mg twice a day for three days)
Trial: 15293971
Drug: Mebendazole (Unibios,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (Unibios, 100 mg twice a day for three days)
Trial: 15293971
Drug: Mebendazole (East
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (East African Pharmaceuticals, 100 mg twice a day for three days)
Trial: 11444712
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine/prilocaine) applied 45 minutes before intravenous cannulation
Trial: 11444712
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied 45 minutes before intravenous cannulation
Trial: 335516
Drug: Cranial irradiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial irradiation plus intrathecal therapy during early remission
Trial: 335516
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate in combination drug treatment
Trial: 27709313
Drug: DA-3031 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-3031 (6 mg on day 2 of each chemotherapy cycle)
Trial: 27709313
Drug: Filgrastim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (100 μg/m2/day for up to 10 days)